- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02235675
Tack Optimized Balloon Angioplasty Below the Knee (TOBA - BTK) Study (TOBABTK)
Prospective, Multicenter Tack Optimized Balloon Angioplasty Below the Knee (TOBA - BTK) Study for Infrapopliteal Arteries Using the Tack-It Endovascular System™
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This first in man (FIM) study is to collect data in support of the safety and performance of the Intact Vascular Tack-It Endovascular System™ for tissue apposition to optimize balloon angioplasty.
Study primary endpoints:
Safety: Composite of Major Adverse Limb Events (MALE) and Peri-procedural Death (POD), assessed at 1 month. Endpoint includes any of the following:
- Major amputation - amputation above the ankle
- Re-intervention (surgical or endovascular) in the target limb
- Procedure-related death - any death within 1 month of the index procedure or any MALE
Device Success: The achievement of successful delivery and deployment of the study device(s) at the intended target site(s) and successful withdrawal of the delivery catheter.
Technical Success: Device success (defined above) and the ability of the Tack to resolve post-PTA dissection, demonstrating angiographic patency at the conclusion of the procedure.
Clinical Success: Ability of the Tack to resolve post-PTA dissection and achieve patency at the conclusion of the procedure, without procedure related complications within 48 hours after the index procedure or at hospital discharge, whichever is sooner.
Study secondary endpoints:
The following events will be assessed at 3, 6 and 12 months:
- All-cause mortality
- Amputation of the limb (above the ankle)
- Amputation free survival
- Clinically driven target vessel revascularization (TVR)
- Clinically driven target lesion revascularization (TLR)
- Changes in Rutherford Clinical Category from baseline
The following parameters will be assessed at 1, 3, 6 and 12 months:
- Maintenance of luminal patency of the target lesion by TBI (≤0.15 decrease) as compared to the baseline TBI obtained prior to discharge
- Doppler Exam (presence of signal)
Study observational endpoint:
The following parameter will be assessed at 6 months (Per local Standard of Care):
• Angiographic percent diameter stenosis
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, A-8036
- Medizinische Universitat Graz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age of subject is >18
- Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the consent form
- Subject has critical limb ischemia (CLI)
- Subject has Rutherford Clinical Category 4-5. (hemodynamic reference)
- Reference vessel diameter below the knee (BTK) is between 1.5mm and 4.5mm (inclusive).
- De-novo target lesion(s) has stenosis >70%.
- Must be able to perform PTA. The PTA must result in a dissection Type A - F at some location along the treatment site.
- Any vessel intervened on must have distal reconstitution above the ankle.
- Inflow Iliac, SFA and Popliteal lesions can be treated during the same procedure using standard angioplasty and/or an approved device. These inflow lesions must be treated first, prior to consideration of treatment of BTK lesions. The patient can be enrolled if the inflow lesions are treated with good angiographic results (must have <30% residual stenosis and no evidence of embolization).
Key Exclusion Criteria:
- The subject has a lesion on the plantar surface of the heel or over the Achilles tendon or has exposed calcaneus.
- The subject has extensive forefoot gangrene / ischemic ulcer that cannot be resolved with standard metatarsal amputation.
- Previous treatment failure of inflow arteries (Iliac, SFA and Popliteal)
- Subject with below knee bypass.
- Subject has significant stenosis or occlusion of inflow vessels tract (proximal disease) not successfully treated (>30% residual stenosis and/or complication of the procedure) prior to BTK angioplasty and patient enrollment.
- Subject is permanently wheel-chair bound or bedridden.
- Subject has an allergy to contrast medium that cannot be pretreated.
- Episode of acute limb ischemia within the previous 30 days.
- Subject is undergoing atherectomy in the target limb or cryoplasty or stenting of BTK treatment site.
- Subject has a systemic infection with positive blood cultures/bacteremia within one week.
- Subject has undrained pus or spreading wet gangrene in the foot that is not controlled at the time of revascularization procedure.
- Subject in whom antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated.
- Myocardial infarction within 30 days prior to enrollment.
- History of stroke within 180 days prior to enrollment.
- Subject has acute or chronic renal disease (e.g., as measured by a serum creatinine of >2.5 mg/dL or >220 umol/L).
- Subject has a known hypersensitivity or contraindication to nitinol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tack-It
Implant of the Intact Vascular Tack-It Endovascular System to repair post angioplasty dissections.
|
Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Endpoints
Time Frame: 30 Days
|
Safety: Composite of Major Adverse Limb Events (MALE) and Peri-procedural Death (POD), assessed at 1 month. Endpoint includes any of the following:
|
30 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Endpoints
Time Frame: 1, 3, 6 and 12 Months
|
The composite of following events will be assessed at 3, 6 and 12 months or as noted:
|
1, 3, 6 and 12 Months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Observational Endpoint
Time Frame: 6 Months
|
The following parameter will be assessed at 6 months (Per local Standard of Care): • Angiographic percent diameter stenosis |
6 Months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marianne Brodmann, MD, Medizinische Universitat Graz
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TD 0109
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Artery Disease
-
Janssen Scientific Affairs, LLCHCA Research Institute, LLCRecruitingCoronary Artery Disease (CAD) | Peripheral Artery Disease (PAD)United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedStructural Heart Disease | Obstructive Coronary Artery Disease | Obstructive Peripheral Artery DiseaseUnited States
-
Helsinki University Central HospitalCompletedPeripheral Artery Occlusive Disease | Peripheral Artery Stenosis | Peripheral Artery RestenosisFinland
-
Michael Lichtenberg, MDCompletedPeripheral Artery Disease (PAD)Germany
-
Fangge DengRecruitingPeripheral Artery Disease (PAD)China
-
Fundacion para la Formacion e Investigacion Sanitarias...Not yet recruiting
-
Rontis Hellas SAPharmassist LtdActive, not recruitingPeripheral Artery Disease (PAD)Greece
-
Boston Scientific CorporationCompletedAtherosclerosis | Peripheral Artery Disease | Plaque, Atherosclerotic | Artery Diseases, Peripheral | Occlusive Arterial DiseaseUnited States, Belgium, Canada, Japan, Austria, New Zealand
-
Seung-Whan Lee, M.D., Ph.D.Active, not recruitingCatheterization, Peripheral | Popliteal Artery | Angioplasty, Balloon | Femoral ArteryKorea, Republic of
-
Dartmouth-Hitchcock Medical CenterSociety for Vascular SurgeryCompletedPeripheral Artery Disease (PAD)United States
Clinical Trials on Tack-It Endovascular System
-
Philips Clinical & Medical Affairs GlobalCompletedPeripheral Artery Disease | Critical Limb IschemiaParaguay
-
Philips Clinical & Medical Affairs GlobalCompleted
-
Philips Clinical & Medical Affairs GlobalCompletedPeripheral Artery DiseaseUnited States, Austria, Netherlands
-
Philips Clinical & Medical Affairs GlobalCompletedPeripheral Arterial DiseaseUnited States, Germany, New Zealand, Hungary, Austria, Czechia
-
Spectranetics CorporationRecruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | PAD | PAD - Peripheral Arterial Disease | Dissection | Arterial DissectionUnited States
-
Philips Clinical & Medical Affairs GlobalCompletedPeripheral Arterial DiseaseGermany, Austria, Belgium, Switzerland
-
China Medical University HospitalRecruitingDelirium | Agitation | Intensive Care Unit DeliriumTaiwan
-
William Cook EuropeCook Group Incorporated; MED Institute, Incorporated; William Cook AustraliaCompletedAortic Dissection Involving the Descending Thoracic AortaItaly, Germany, Australia, Czech Republic, France
-
Massachusetts General HospitalNational Cancer Institute (NCI)CompletedA Mammography FastTrack Program in Increasing the Number of Women Undergoing Breast Cancer ScreeningBreast CancerUnited States
-
OmniSonics Medical Technologies, Inc.Unknown